Edarbi: a new angiotensin II antagonist
27 Apr 2012
Edarbi (azilsartan medoxomil) is indicated for the treatment of essential hypertension in adults.
The investigational antidepressant vortioxetine has shown promising results in elderly patients.
Edarbi (azilsartan medoxomil) is indicated for the treatment of essential hypertension in adults.
Esmya (ulipristal acetate) has been launched for the pre-operative treatment of moderate to severe symptoms of uterine fibroids in women of reproductive age.
All strengths of Becodisks (beclometasone diproprionate) have been discontinued by GlaxoSmithKline following a decline in demand.
The National Institute for Health and Clinical Excellence (NICE) has decided that eribulin (Halaven) should not be made available on the NHS.
A review into the safety of strontium ranelate (Protelos) with regard to venous thromboembolism (VTE) and serious skin reactions has been completed by the EMA.
Remicade (infliximab) is now licensed for the treatment of severe active ulcerative colitis in children aged 6-17 years.
To avoid accidental overdose with Perfalgan (paracetamol) 10mg/ml solution for infusion, prescribers are recommended to specify the volume of administration in ml.
Teysuno (tegafur/gimeracil/oteracil) is indicated for use in combination with cisplatin for advanced gastric cancer.
Sort results by: date | relevance
Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.